SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
PHASE I CLINICAL RESEARCH RESULTS OF INNOVATIVE DRUG TQH2722 (IL-4Rα mAb) PRESENTED

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that, the Phase I clinical research results of TQH2722 (IL-4Rα mAb), an innovative drug developed by the Group, was presented at the 2023 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference.

Phase I Clinical Results of TQH2722

The Phase I clinical research (TQH2722-I-01) was designed to evaluate the safety, tolerability, pharmacokinetic profile and immunogenicity of TQH2722 in healthy adult subjects following single/multiple administrations. The data presented at this RAD conference were unblinded safety results and pharmacokinetic data.

Research method:

Single dose-escalation studies were conducted from a 50 mg dose to a 1200 mg dose; multiple dosing dose groups were given 150 mg and 600 mg multiple dosing (1 dose every 2 weeks for a total of 4 doses); and safety evaluations were continued until 8 weeks after the final dose. Enrollment of all 66 subjects was completed, with 52 (78.8%) subjects receiving TQH2722 administration and 14 (21.2%) subjects receiving placebo administration.

The results of the research showed that:

– TQH2722 showed good safety and tolerability. There were no SAEs (serious adverse events) or TEAEs (treatment emergent adverse events) leading to discontinuation of the drug. Adverse events were dominated by injection site reactions and abnormalities in various tests, with most of them resolved spontaneously.

– TQH2722 exhibited a nonlinear target-mediated pharmacokinetic profile, with exposures increasing in a greater than dose-proportional manner, and the half-life of a single subcutaneous administration of 50-1200 mg of TQH2722 was approximately 4-18 days.

Such data support the further clinical development of TQH2722 as a therapeutic agent for atopic dermatitis and other related diseases mediated by Th2 inflammation.

Status of the Phase II Clinical Research of TQH2722

The Phase II clinical research of TQH2722 in subjects with atopic dermatitis (TQH2722-II-01) has completed enrollment of all subjects as planned, with results scheduled to be published in 2024. Meanwhile, a Phase II study (TQH2722-II-02) for the chronic sinusitis indication is already underway in parallel.

About TQH2722 (IL-4Rα mAb)

TQH2722 is a humanized monoclonal antibody targeting interleukin 4 receptor α (IL-4Rα) jointly developed by Chia Tai-Tianqing Pharmaceutical Holdings Nanjing Shunxin Pharmaceutical Co., Ltd. (正大天晴藥業集團南京順欣製藥有限公司), a subsidiary of the Group, and Biosion, Inc. (博奧信生物技術(南京)有限公司), which can lead to dual blockade of interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and inhibit the type 2 inflammatory pathway, thus achieving the purpose of controlling type 2 inflammatory diseases, such as atopic dermatitis, asthma, and chronic sinusitis.

The Group has always been adhering to the brand mission of "Healthy Technology, Giving Warm to More Lives" and is committed to safeguarding people's health with products of excellent quality and providing patients with quality and economical domestic medicines. We will continue to accelerate the research and development process of TQH2722 and strive to provide more choices for patients with chronic inflammatory diseases as soon as possible.

Note: RAD website for meeting abstracts and e-posters

https://revolutionizingad.com/education-resources/december-2023-abstracts-and-posters

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 12 December 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.